# US 2014/0194368 A1 · Method of Treating Cancer by Administration of Low Levels of Heat Shock Protein 70 (HSP70)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0194368 A1
- Document ID: US20140194368A1
- Status: Published application
- Kind: A1
- Application number: 13/733,946
- Filed: 2013-01-04
- Published: 2014-07-10
- Earliest claimed: 2013-01-04
- Assignees: Beech Tree Labs, Inc.
- Applicants: Beech Tree Labs, Inc.
- Inventors: John McMichael
- Web page: https://patentgrep.com/patent/US20140194368A1

## CPC

- A61K 38/1709: {from mammals}
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention is directed to methods of treating cancer by administration of heat shock protein 70 (Hsp70) to the subject suffering from cancer.

## Claims

### Claim 1

A method of treating cancer in a subject in need thereof comprising:
administering an effective amount of heat shock protein 70 (Hsp70) to said subject.

### Claim 2 (depends on 1)

The method of claim 1 wherein the subject is human.

### Claim 3 (depends on 1)

The method of claim 1 wherein the cancer is selected from the group of cancers comprising brain tumors (including meningiomas, glioblastoma multiforme, anaplastic astrocytomas, cerebellar astrocytomas, other high-grade or low-grade astrocytomas, brain stem gliomas, oligodendrogliomas, mixed gliomas, other gliomas, cerebral neuroblastomas, craniopharyngiomas, diencephalic gliomas, germinomas, medulloblastomas, ependymomas. choroid plexus tumors, pineal parenchymal tumors, gangliogliomas, neuroepithelial tumors, neuronal or mixed neuronal glial tumors), lung tumors (including small cell carcinomas, epidermoid carcinomas, adenocarcinomas, large cell carcinomas, carcinoid tumors, bronchial gland tumors, mesotheliomas, sarcomas or mixed tumors), prostate cancers (including adenocarcinomas, squamous cell carcinoma, transitional cell carcinoma, carcinoma of the prostatic utricle, or carcinosarcomas), breast cancers (including adenocarcinomas or carcinoid tumors), or gastric, intestinal, or colon cancers (including adenocarcinomas, invasive ductal carcinoma, infiltrating or invasive lobular carcinoma, medullary carcinoma, ductal carcinoma in situ, lobular carcinoma in situ, colloid carcinoma or Paget's disease of the nipple), skin cancer (including melanoma, squamous cell carcinoma, tumor progression of human skin keratinocytes, basal cell carcinoma, hemangiopericytoma and Karposi's sarcoma), lymphoma (including Hogkin's disease and non-Hodgkin's lymphoma), sarcomas (including osteosarcoma, chondrosarcoma and fibrosarcoma).

### Claim 4 (depends on 1)

The method of claim 1 wherein the cancer is a brain tumor.

### Claim 5 (depends on 1)

The method of claim 1 wherein the Hsp70 is administered at a dosage of from 0.0003 micrograms to 3 micrograms per day.

### Claim 6 (depends on 1)

The method of claim 1 wherein the Hsp70 is administered at a dosage of from 0.003 micrograms to 0.3 micrograms per day.

### Claim 7 (depends on 1)

The method of claim 1 wherein the Hsp70 is administered by is administered by a mode selected from the group consisting of sublingual, bucal, oral drench, subcutaneous, intramuscular, intradermal, or intravenous.

### Claim 8 (depends on 1)

The method of claim 1 wherein the Hsp70 is administered sublingually.

### Claim 9 (depends on 1)

The method of claim 1 wherein the Hsp70 is administered in the absence of other cancer therapeutics.

### Claim 10 (depends on 1)

The method of claim 1 wherein the Hsp70 is administered in the absence of any vaccine.

### Claim 11 (depends on 1)

The method of claim 1 wherein the Hsp70 is not complexed to any other molecule.